» Articles » PMID: 34831438

On the Role of the Immunoproteasome in Protein Homeostasis

Overview
Journal Cells
Publisher MDPI
Date 2021 Nov 27
PMID 34831438
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous cellular processes are controlled by the proteasome, a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells, through regulated protein degradation. The immunoproteasome is a special type of proteasome which is inducible under inflammatory conditions and constitutively expressed in hematopoietic cells. MECL-1 (β2i), LMP2 (β1i), and LMP7 (β5i) are the proteolytically active subunits of the immunoproteasome (IP), which is known to shape the antigenic repertoire presented on major histocompatibility complex (MHC) class I molecules. Furthermore, the immunoproteasome is involved in T cell expansion and inflammatory diseases. In recent years, targeting the immunoproteasome in cancer, autoimmune diseases, and transplantation proved to be therapeutically effective in preclinical animal models. However, the prime function of standard proteasomes and immunoproteasomes is the control of protein homeostasis in cells. To maintain protein homeostasis in cells, proteasomes remove proteins which are not properly folded, which are damaged by stress conditions such as reactive oxygen species formation, or which have to be degraded on the basis of regular protein turnover. In this review we summarize the latest insights on how the immunoproteasome influences protein homeostasis.

Citing Articles

PI31 is a positive regulator of 20S immunoproteasome assembly.

Wang J, Kjellgren A, DeMartino G bioRxiv. 2025; .

PMID: 39868238 PMC: 11761684. DOI: 10.1101/2025.01.15.633194.


Synthesis and Application of a Caged Bioluminescent Probe for the Immunoproteasome.

Loy C, Trader D Curr Protoc. 2024; 4(11):e70057.

PMID: 39574360 PMC: 11648997. DOI: 10.1002/cpz1.70057.


Psmb8 inhibits mitochondrial fission and alleviates myocardial ischaemia/reperfusion injury by targeting Drp1 degradation.

Su H, Xu L, Li P, Bi H, Jiang W, Li H Cell Death Dis. 2024; 15(11):803.

PMID: 39516219 PMC: 11549449. DOI: 10.1038/s41419-024-07189-1.


Immunoproteasome acted as immunotherapy 'coffee companion' in advanced carcinoma therapy.

Shi S, Ou X, Liu C, Wen H, Jiang K Front Immunol. 2024; 15:1464267.

PMID: 39281672 PMC: 11392738. DOI: 10.3389/fimmu.2024.1464267.


Human Beta Defensin-2 mRNA and Proteasome Subunit β Type 8 mRNA Analysis, Useful in Differentiating Skin Biopsies from Atopic Dermatitis and Psoriasis Vulgaris Patients.

Terlikowska-Brzosko A, Galus R, Murawski P, Niderla-Bielinska J, Mlynarczuk-Bialy I, Paluchowska E Int J Mol Sci. 2024; 25(17).

PMID: 39273140 PMC: 11395582. DOI: 10.3390/ijms25179192.


References
1.
Wang X, Chemmama I, Yu C, Huszagh A, Xu Y, Viner R . The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress. J Biol Chem. 2017; 292(39):16310-16320. PMC: 5625060. DOI: 10.1074/jbc.M117.803619. View

2.
Kwak M, Wakabayashi N, Greenlaw J, Yamamoto M, Kensler T . Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol. 2003; 23(23):8786-94. PMC: 262680. DOI: 10.1128/MCB.23.23.8786-8794.2003. View

3.
Li J, Koerner J, Basler M, Brunner T, Kirk C, Groettrup M . Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int. 2019; 95(3):611-623. DOI: 10.1016/j.kint.2018.10.022. View

4.
Mao X, Green J, Safer B, LINDSTEN T, Frederickson R, Miyamoto S . Regulation of translation initiation factor gene expression during human T cell activation. J Biol Chem. 1992; 267(28):20444-50. View

5.
Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, Gomez-Ramos P, Moran M, Castano J . Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci. 2003; 23(37):11653-61. PMC: 6740941. View